Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON (JNJ)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

Johnson & Johnson : stoffels, paulus

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/21/2018 | 01:56am CET

FORM 4

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5


1. Name and Address of Reporting Person * Stoffels Paulus 2. Issuer Name and Ticker or Trading Symbol JOHNSON & JOHNSON [ JNJ ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner
__ X __ Officer (give title below) _____ Other (specify below)
Exec VP, Chief Scientific Off
ONE JOHNSON & JOHNSON PLAZA 3. Date of Earliest Transaction (MM/DD/YYYY)
NEW BRUNSWICK, NJ 08933 4. If Amendment, Date Original Filed (MM/DD/YYYY) 6. Individual or Joint/Group Filing (Check Applicable Line) _ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 2/15/2018 M 155342.0000 A $90.4400 357906.3468 D
Common Stock 2/15/2018 S 155342.0000 D $129.8580 (1) 202564.3468 D
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Options (Right to Buy) $90.4400 2/15/2018 M 155342.0000 2/11/2017 2/9/2024 Common Stock 155342.0000 $0.0000 0.0000 D

Explanation of Responses:
(1) This transaction was executed in multiple trades at prices ranging from $129.435 to $130.43. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Reporting Owners
Reporting Owner Name / Address
Director 10% Owner Officer Other
Stoffels Paulus
ONE JOHNSON & JOHNSON PLAZA
NEW BRUNSWICK, NJ 08933
Exec VP, Chief Scientific Off

Signatures
Linda E. King, as attorney-in-fact for Paulus Stoffels 2/20/2018
** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Johnson & Johnson published this content on 20 February 2018 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 21 February 2018 00:55:07 UTC.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
01:56aJOHNSON & JOHNSON : stoffels, paulus
PU
02/20JOHNSON & JOHNSON : to Participate in Cowen 38th Annual Healthcare Conference
PR
02/20JOHNSON & JOHNSON : to Participate in Cowen 38th Annual Healthcare Conference
PU
02/20JNJ Law Offices of Howard G. Smith Continues Investigation on Behalf of Johns..
BU
02/20JOHNSON & JOHNSON : The Janssen Pharmaceutical - New TREMFYA Data Demonstrates L..
AQ
02/19JOHNSON & JOHNSON : ERLEADA, a Next-Generation Androgen Receptor Inhibitor, Gran..
AQ
02/19JOHNSON & JOHNSON : How Johnson & Johnson Is Doing Its Part to Tackle the Worldw..
AQ
02/18OUTLOOK 2018 : A mother channels a loss unlike any other into a force to help ot..
AQ
02/18ABBVIE : Stocks’ Win Streak Extends to Six Days
AQ
02/16JOHNSON & JOHNSON : Stocks stretch winning streak to 6 days despite turbulence
AQ
More news
News from SeekingAlpha
02/20BIOTECHS : Still Well Placed For More Gains 
02/19Healthcare In Transition 
02/19YOUR DAILY PHARMA SCOOP : AbbVie's Upadacitinib, Johnson & Johnson's Tremfya, Ce.. 
02/19Why Stryker Will Likely Continue Delivering Strong Growth 
02/18RETIREMENT STRATEGY : How To Have Enough And Which Stocks To Own 
Financials ($)
Sales 2018 81 103 M
EBIT 2018 24 826 M
Net income 2018 19 539 M
Debt 2018 11 371 M
Yield 2018 2,72%
P/E ratio 2018 18,47
P/E ratio 2019 17,26
EV / Sales 2018 4,55x
EV / Sales 2019 4,19x
Capitalization 358 B
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 151 $
Spread / Average Target 13%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-7.19%357 710
NOVARTIS-3.37%224 785
PFIZER-2.84%216 135
ROCHE HOLDING LTD.-9.37%207 160
MERCK AND COMPANY-0.50%153 359
AMGEN3.23%133 241